5 stories mentioning HKG:2269Updated 22d ago
Every FINWIRES story that references HKG:2269, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
WuXi Biologics (Cayman) (HKG:2269) has an average rating of overweight and mean price target of HK$50.15, according to analysts polled by FactSet.
WuXi Biologics (Cayman) (HKG:2269) reported 3.31 billion yuan in adjusted profit attributable to owners for the first half, compared with 2.39 billion yuan a year ago, a Tuesday bourse filing showed.Adjusted EPS moved to 0.78 yuan from 0.56 yuan year over year.For the six months ended June 30, revenue was 11.8 billion yuan, versus 9.95 billion yuan previously, the biotechnology company said.
WuXi Biologics (Cayman) (HKG:2269) has an average rating of overweight and mean price target of HK$48.50, according to analysts polled by FactSet.
CANbridge Pharmaceuticals (HKG:1228) entered service procurement framework agreements with WuXi Biologics and Baheal Medical, according to a Tuesday Hong Kong bourse filing.Under the agreement, WuXi Biologics (HKG:2269) will provide contract research, development, and manufacturing organization services to CANbridge through 2028.Meanwhile, Baheal Medical will provide logistics, warehousing, and other supporting services through 2028.
WuXi Biologics (Cayman) (HKG:2269) said it plans to buy back up to $400 million of its shares from the open market, according to a filing with the Hong Kong bourse.The company said its current share price does not reflect its intrinsic value, representing a good opportunity to conduct the buyback.The company's shares were up over 4% in recent morning trade.
